Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 4/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.51 |
| ▸ | ITGAV | P06756 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520629 | 0.85 | ITGB3 (0.52) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL12572489 | 0.85 | ITGB3 (0.52) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL29060375 | 0.84 | ALDH1A1 (0.62) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL8065362 | 0.84 | ALDH1A1 (0.62) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL8349459 | 0.84 | ALDH1A1 (0.62) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL2014415 | 0.83 | FPR2 (0.53) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL29664208 | 0.83 | ITGB1 (0.71) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL19581783 | 0.83 | MAPK1 (0.68) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL2440136 | 0.83 | FPR2 (0.53) | ITGB1ITGA5ITGB3ITGAVMAPK1 | |
| SCHEMBL19581784 | 0.83 | MAPK1 (0.68) | ITGB1ITGA5ITGB3ITGAVMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964749-B2 | Process for obtaining valine derivatives useful for obtaining a pharmaceutically active compound | INKE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| US-20100240919-A1 | Process For Obtaining Valine Derivatives Useful For Obtaining A Pharmaceutically Active Compound | INKE, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| US-7728021-B2 | Process for the preparation of Valsartan and precursors thereof | INKE, S.A. (ES) | 2010-06-01 | — | — | US | disclosed |
| EP-1937654-B1 | PROCESS FOR OBTAINING VALINE DERIVATIVES USEFUL FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND | INKE SA (ES) | 2009-11-11 | — | — | EP | disclosed |
| US-20090221836-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | INKE, S.A. (ES) | 2009-09-03 | — | — | US | disclosed |
| EP-1747190-B1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | INKE SA (ES) | 2008-07-16 | — | — | EP | disclosed |
| EP-1937654-A1 | PROCESS FOR OBTAINING VALINE DERIVATIVES USEFUL FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND | INKE, S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007045675-A1 | PROCESS FOR OBTAINING VALINE DERIVATIVES USEFUL FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND | INKE, S.A. (ES) | 2007-04-26 | — | — | WO | disclosed |
| EP-1747190-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | INKE, S.A. (ES) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005102987-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | INKE, S.A. (ES) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240919-A1 | Process For Obtaining Valine Derivatives Useful For Obtaining A Pharmaceutically Active Compound | AGT, AVPR2, AGTR2 | ITGB1 2587/4885ITGA5 1905/4885ITGB3 501/4885 |
| US-20090221836-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | REN, AGT, NPPA | ITGB1 4045/4885ITGA5 1658/4885ITGB3 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.